CIP2A as a biomarker in detection of cervical cancer
    19.
    发明授权
    CIP2A as a biomarker in detection of cervical cancer 有权
    CIP2A作为检测宫颈癌的生物标志物

    公开(公告)号:US08900813B2

    公开(公告)日:2014-12-02

    申请号:US13199019

    申请日:2011-08-17

    申请人: Lisa P. Huang

    发明人: Lisa P. Huang

    摘要: The present invention provides methods and compositions for detecting cervical cancer in a human. The present invention provides CIP2A as a biomarker detectable in a biological sample from cervix of an individual, an increased expression of same is an indication of cervical cancer in the individual. CIP2A mRNA or protein can both serve as reliable biomarkers. In one embodiment, the present invention provides a combined use of CIP2A with at least one additional biomarker selected from the group consisting of Ki67, TOP2A, MCM2, MCM5, p14ARF and p16INK4a, to better serve as a detection means for cervical cancer. The present invention provides a reliable and accurate assay methods and compositions which may be used for detecting cervical cancer in an individual with a high sensitivity and specificity. The present assay provides a novel use of CIP2A as a tool for early detection of cervical cancer in humans.

    摘要翻译: 本发明提供了用于检测人类宫颈癌的方法和组合物。 本发明提供CIP2A作为在个体宫颈生物样品中可检测的生物标志物,其增加的表达是个体中子宫颈癌的指征。 CIP2A mRNA或蛋白质均可作为可靠的生物标志物。 在一个实施方案中,本发明提供CIP2A与至少一种选自Ki67,TOP2A,MCM2,MCM5,p14ARF和p16INK4a的另外的生物标志物的组合使用,以更好地用作子宫颈癌的检测手段。 本发明提供了可用于检测具有高灵敏度和特异性的个体中的子宫颈癌的可靠和精确的测定方法和组合物。 本测定提供了CIP2A作为人类早期检测子宫颈癌的工具的新用途。

    CIP2A as a biomarker in detection of cervical cancer
    20.
    发明申请
    CIP2A as a biomarker in detection of cervical cancer 有权
    CIP2A作为检测宫颈癌的生物标志物

    公开(公告)号:US20120070837A1

    公开(公告)日:2012-03-22

    申请号:US13199019

    申请日:2011-08-17

    IPC分类号: C12Q1/68 G01N33/566

    摘要: The present invention provides methods and compositions for detecting cervical cancer in a human. The present invention provides CIP2A as a biomarker detectable in a biological sample from cervix of an individual, an increased expression of same is an indication of cervical cancer in the individual. CIP2A mRNA or protein can both serve as reliable biomarkers. In one embodiment, the present invention provides a combined use of CIP2A with at least one additional biomarker selected from the group consisting of Ki67, TOP2A, MCM2, MCM5, p14ARF and p16INK4a, to better serve as a detection means for cervical cancer. The present invention provides a reliable and accurate assay methods and compositions which may be used for detecting cervical cancer in an individual with a high sensitivity and specificity. The present assay provides a novel use of CIP2A as a tool for early detection of cervical cancer in humans.

    摘要翻译: 本发明提供了用于检测人类宫颈癌的方法和组合物。 本发明提供CIP2A作为在个体宫颈生物样品中可检测的生物标志物,其增加的表达是个体中子宫颈癌的指征。 CIP2A mRNA或蛋白质均可作为可靠的生物标志物。 在一个实施方案中,本发明提供CIP2A与至少一种选自Ki67,TOP2A,MCM2,MCM5,p14ARF和p16INK4a的另外的生物标志物的组合使用,以更好地用作子宫颈癌的检测手段。 本发明提供了可用于检测具有高灵敏度和特异性的个体中的子宫颈癌的可靠和精确的测定方法和组合物。 本测定提供了CIP2A作为人类早期检测子宫颈癌的工具的新用途。